The Satellite Symposium, titled ‘Targeting BTK across B-cell malignancies – Selecting the right treatment for patients with lymphoma or CLL’, was chaired by Professor Stephan Stilgenbauer and it provided an overview of current and emerging BTKi-based treatments for B-cell malignancies with a particular focus on chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Professor Stilgenbauer presented the treatment landscape for CLL patients. He discussed continuous versus fixed duration treatment, switching from first to next generation BTKis, and how genetic subtypes influence treatment selection. Professor Zinzani presented the current treatment status in relapsed/refractory (R/R) FL including emerging data from ongoing clinical trials. Professor Stilgenbauer led the panel discussion with the full faculty, including Professor Davide Rossi and Professor Marie José Kersten, to discuss, supported by additional patient cases, the key criteria for selecting a BTKi versus other treatment options for CLL, FL, MZL and WM, especially for difficult-to-treat patients.